These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15201384)

  • 21. [Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis].
    Débat Zoguéreh D; Boucraut J; Beau-Salinas F; Bodiguel E; Lechapois D; Pomet E
    Rev Neurol (Paris); 2004 Nov; 160(11):1081-4. PubMed ID: 15602352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
    Mikol D; Lopez-Bresnahan M; Taraskiewicz S; Chang P; Rangnow J;
    Mult Scler; 2005 Oct; 11(5):585-91. PubMed ID: 16193898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.
    Dionisiotis J; Zoukos Y; Thomaides T
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1079. PubMed ID: 15201386
    [No Abstract]   [Full Text] [Related]  

  • 24. Erythema elevatum et diutinum, multiple sclerosis and interferon beta.
    Gil M; Chizzolini C; Kaya G; Hauser C
    Dermatology; 2004; 209(1):75-6. PubMed ID: 15237277
    [No Abstract]   [Full Text] [Related]  

  • 25. Rebif offers another option for treating multiple sclerosis.
    Ryan M
    J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
    [No Abstract]   [Full Text] [Related]  

  • 26. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Embolia cutis medicamentosa following interferon beta injection.
    Koontz D; Alshekhlee A
    Mult Scler; 2007 Nov; 13(9):1203-4. PubMed ID: 17967846
    [No Abstract]   [Full Text] [Related]  

  • 29. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
    Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
    Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 31. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
    Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon beta retinopathy in a patient with multiple sclerosis.
    Post JW; Colleaux K
    Can J Ophthalmol; 2009 Oct; 44(5):e37. PubMed ID: 19798812
    [No Abstract]   [Full Text] [Related]  

  • 33. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis.
    Rieckmann P; O'Connor P; Francis GS; Wetherill G; Alteri E
    Drug Saf; 2004; 27(10):745-56. PubMed ID: 15350158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases.
    Ball NJ; Cowan BJ; Hashimoto SA
    J Cutan Pathol; 2009 Mar; 36(3):331-7. PubMed ID: 19032383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
    Kocer B; Nazliel B; Oztas M; Batur HZ
    Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
    [No Abstract]   [Full Text] [Related]  

  • 40. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
    Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
    Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.